Compare Stocks: BLRX, BKHA, GOSS, and ALGS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.86 -15.2%	$5.87	$3.98 ▼ $13.69	$36.57M	2.31	156,883 shs	98,670 shs
BKHA Black Hawk Acquisition	$11.97 +1.0%	$12.23	$11.00 ▼ $13.10	$49.68M	0.04	2,883 shs	244 shs
BLRX BioLineRx	$2.80 +7.7%	$2.92	$2.15 ▼ $4.56	$12.23M	1.54	29,395 shs	214,338 shs
GOSS Gossamer Bio	$0.17 -0.1%	$0.17	$0.11 ▼ $3.87	$39.90M	2.04	18.84 million shs	10.10 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+3.60%	+63.36%	+29.16%	-34.50%
BKHA Black Hawk Acquisition	0.00%	-0.34%	-0.29%	-0.25%	+7.43%
BLRX BioLineRx	0.00%	-7.47%	-7.80%	-25.29%	-31.40%
GOSS Gossamer Bio	0.00%	+9.95%	+0.35%	-14.13%	-93.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.86 -15.2%	$5.87	$3.98 ▼ $13.69	$36.57M	2.31	156,883 shs	98,670 shs
BKHA Black Hawk Acquisition	$11.97 +1.0%	$12.23	$11.00 ▼ $13.10	$49.68M	0.04	2,883 shs	244 shs
BLRX BioLineRx	$2.80 +7.7%	$2.92	$2.15 ▼ $4.56	$12.23M	1.54	29,395 shs	214,338 shs
GOSS Gossamer Bio	$0.17 -0.1%	$0.17	$0.11 ▼ $3.87	$39.90M	2.04	18.84 million shs	10.10 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+3.60%	+63.36%	+29.16%	-34.50%
BKHA Black Hawk Acquisition	0.00%	-0.34%	-0.29%	-0.25%	+7.43%
BLRX BioLineRx	0.00%	-7.47%	-7.80%	-25.29%	-31.40%
GOSS Gossamer Bio	0.00%	+9.95%	+0.35%	-14.13%	-93.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	557.00% Upside
BKHA Black Hawk Acquisition	1.00	Sell	N/A	N/A
BLRX BioLineRx	1.00	Sell	N/A	N/A
GOSS Gossamer Bio	2.22	Hold	$3.20	1,782.35% Upside

Current Analyst Ratings Breakdown

Latest BLRX, BKHA, GOSS, and ALGS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	BKHA Black Hawk Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/17/2026	BLRX BioLineRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$2.19M	16.70	N/A	N/A	$8.67 per share	0.68
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
BLRX BioLineRx	$1.40M	8.72	N/A	N/A	$5.36 per share	0.52
GOSS Gossamer Bio	$48.47M	0.82	N/A	N/A	($0.53) per share	-0.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BLRX BioLineRx	-$1.17M	-$1.92	N/A	N/A	N/A	-563.70%	-37.73%	-19.42%	8/31/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$0.70	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)

Latest BLRX, BKHA, GOSS, and ALGS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/31/2026	Q2 2026	BLRX BioLineRx	-$0.15	-$0.77	-$0.62	-$0.77	$0.50 million	$0.29 million
8/13/2026	Q2 2026	GOSS Gossamer Bio	-$0.1234	-$0.08	+$0.0434	-$0.08	$3.63 million	$9.24 million
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million
7/15/2026	Q2 2026	BKHA Black Hawk Acquisition	N/A	$0.02	N/A	$0.02	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
BKHA Black Hawk Acquisition	N/A	N/A	N/A
BLRX BioLineRx	0.16	1.58	1.43
GOSS Gossamer Bio	N/A	0.53	0.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
BKHA Black Hawk Acquisition	N/A
BLRX BioLineRx	1.56%
GOSS Gossamer Bio	81.23%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
BKHA Black Hawk Acquisition	N/A
BLRX BioLineRx	1.10%
GOSS Gossamer Bio	3.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.24 million	5.76 million	No Data
BKHA Black Hawk Acquisition	N/A	4.15 million	N/A	N/A
BLRX BioLineRx	40	4.37 million	4.32 million	Optionable
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable

BLRX, BKHA, GOSS, and ALGS Headlines

Recent News About These Companies

Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of "Hold" from Analysts

August 31 at 4:11 AM | americanbankingnews.com

HC Wainwright Has Weak Forecast for Gossamer Bio Q3 Earnings

August 30 at 1:13 AM | americanbankingnews.com

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

August 28 at 12:11 PM | finance.yahoo.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS) and Biohaven Ltd. (BHVN)

August 27, 2026 | theglobeandmail.com

Gossamer Bio Amends Charter for New Preferred Financing

August 26, 2026 | tipranks.com

Gossamer Bio announces $250m in funding to advance seralutinib

August 24, 2026 | finance.yahoo.com

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

August 21, 2026 | uk.finance.yahoo.com

Gossamer Bio (NASDAQ:GOSS) Funding Move Signals Biotech Shift

August 21, 2026 | kalkinemedia.comK

Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

August 21, 2026 | finance.yahoo.com

Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

August 21, 2026 | finance.yahoo.com

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

August 13, 2026 | zacks.com

Gossamer Bio: Q2 Earnings Snapshot

August 13, 2026 | sfgate.com

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | finance.yahoo.com

Gossamer Bio Inc.

August 13, 2026 | marketwatch.com

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

August 10, 2026 | prnewswire.com

Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update

August 1, 2026 | finance.yahoo.com

Gossamer Bio (GOSS) Receives a Hold from Wedbush

July 30, 2026 | theglobeandmail.com

Cary company ends $160M drug collaboration

July 30, 2026 | bizjournals.com

Gossamer Bio, Inc. (GOSS) Stock Price, News, Quote & History - Yahoo Finance

July 28, 2026 | finance.yahoo.com

Gossamer Bio accentue ses gains en pré-séance après l'annonce du dépôt d'une demande de mise sur le marché pour son traitement de l'hypertension artérielle pulmonaire

July 28, 2026 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, BKHA, GOSS, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$5.86 -1.05 (-15.20%)

As of 04:00 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Black Hawk Acquisition NASDAQ:BKHA

$11.97 +0.12 (+1.01%)

As of 11:28 AM Eastern

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

BioLineRx NASDAQ:BLRX

$2.80 +0.20 (+7.69%)

As of 04:00 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Gossamer Bio NASDAQ:GOSS

$0.17 0.00 (-0.06%)

As of 04:00 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BLRX, BKHA, GOSS, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BLRX, BKHA, GOSS, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BLRX, BKHA, GOSS, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, BKHA, GOSS, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Black Hawk Acquisition NASDAQ:BKHA

BioLineRx NASDAQ:BLRX

Gossamer Bio NASDAQ:GOSS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BLRX, BKHA, GOSS, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BLRX, BKHA, GOSS, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BLRX, BKHA, GOSS, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, BKHA, GOSS, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Black Hawk Acquisition NASDAQ:BKHA

BioLineRx NASDAQ:BLRX

Gossamer Bio NASDAQ:GOSS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools